Citi said Divi's has an integrated and cost-efficient peptide manufacturing platform, which could provide an advantage as demand for peptide-based therapies expands.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.